Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials

Qi, Wei-Xiang; Tang, Lina; He, Aina; Yao, Yang; Shen, Zan

doi:10.1007/s10147-013-0561-6

Cited by 174 publications

(117 citation statements)

References 51 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…The risk of ONJ in cancer patients in clinical trials was 0-0.019% (0-1.9 cases per 10,000 cancer patients) [10][11][12] , while the risk of ONJ in cancer patients on denosumab treatment was comparable to that of patients receiving zolendronate [13][14][15] . The risk of ONJ among osteoporosis patients treated with zolendronate or denosumab (0.017-0.04%) was similar to that of patients enrolled (0-0.02%) 8) .…”

Section: Histological Evaluationmentioning

confidence: 97%

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Sukegawa

Kanno

Kawai

et al. 2016

J. Hard Tissue Biology.

View full text Add to dashboard Cite

In 2014, the American Association of Oral and Maxillofacial Surgery recommended surgical treatment for medication-related osteonecrosis of the jaw (MRONJ) patients classified as stage 3 or those with mobile segments of bony sequestrum. However, there is limited information regarding the healing mechanism in MRONJ surgical treatments. This study aimed to retrospectively elucidate clinical outcomes of the surgical treatment of MRONJ patients. This study included 26 patients (7 men, 19 women; age: 42-92 years; mean ± standard deviation, 75.3 ± 11.7 years) who were classified as stage 3 or had mobile segments of bony sequestrum, and intake of the offending drug was ceased. The sequestrum was removed with surrounding vital bone, and segmental resection was performed in one patient with a pathological mandibular fracture. The outcome was classified into one of the following three categories: "Healing," "Improvement," "Unchanged." and "Exacerbation." The mean postoperative follow-up period was 16.6 months (3.0 -57.9 months), and complete healing was observed in 21 patients (80.8%), improvement of the lesion was observed in four patients (15.4%), and the outcome of one patient was unchanged (3.8%). The procedure described here may be recommended with relatively high clinical success rate for the patients with MRONJ requiring surgical treatment.

show abstract

Section: Histological Evaluationmentioning

confidence: 97%

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Sukegawa

Kanno

Kawai

et al. 2016

J. Hard Tissue Biology.

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis suggested that patients with prostate cancer have 3 times higher risk compared to other types of cancer, probably linked to anemia and frequent use of corticosteroid. 7 In the case of breast cancer, concomitant use of drugs that reduce bone turnover (aromatase inhibitors) is an additional risk factor. In any case, the safety profile of DMab after long-term exposure is 19.1 months in breast cancer and 12 months in prostate cancer.…”

Section: Stagementioning

confidence: 99%

“…A recent meta-analysis reports that the mean incidence of DRONJ in over 5700 cancer patients is 1.8% vs 1.3% in the zoledronic acid arm. 7 In contrast, during treatment of osteoporosis every 6 months with DMab, the occurrence of ONJ is very rare. In the FREEDOM study, no cases of ONJ occurred in 7000 women within 3 years of follow-up.…”

mentioning

confidence: 99%

Multifocal brown tumor of the maxilla and mandible in primary hyperparathyroidism – diagnostic challenges and literature review

Gogolewski¹,

Jędrusik-Pawłowska²,

Drozdzowska³

2017

Dent. Med. Probl.

View full text Add to dashboard Cite

Osteonecrosis of the jaw (ONJ) is a rare treatment-related side effect of anti-resorptive drugs whose risk is increased by concomitant local and systemic factors. The number of cases of medication-related ONJ is constantly increasing as a result of the rising tide of molecular-targeted and immunological drugs used in cancer treatment. Denosumab-related ONJ presents peculiar pathophysiological, histopathological, clinical, and therapeutic features compared to that induced by bisphosphonates-related ONJ.This study aimed to compare ONJ induced by denosumab to that caused by bisphosphonates. We have reviewed the literature of the last 5 years on denosumab-related ONJ, focusing on reviews and metaanalyses.The physiopathology of ONJ is unclear. Denosumab acts on receptor activator of nuclear factor kappa-B ligand (RANKL) to inhibit the formation and activity of osteoclasts. The reduction of bone turnover seems to play an important role. Dentists and oral surgeons in the coming years will see an increasing number of patients who are receiving treatment potentially toxic to bone, but also require good dental care. Early recognition of ONJ is essential in the patient's treatment with denosumab, therefore a close collaboration between the dentist and oncologist is fundamental.

show abstract

“…After the publication of the above-mentioned studies and other reports of jaw osteonecrosis in patients using denosumab and bevacizumab, [31][32][33][34][35] the AAOMS published a second update on its guidelines, establishing a new definition for the disorder. The new definition associated osteonecrosis of the jaw with not only bisphosphonates but also other antiresorptive and antiangiogenic drugs.…”

mentioning

confidence: 99%

Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity

Koth¹,

Figueiredo²,

Salum³

et al. 2016

Dentomaxillofacial Radiology

View full text Add to dashboard Cite

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials

Cited by 174 publications

References 51 publications

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

A Clinical Retrospective Study of Surgical Treatment for Medication-Related Osteonecrosis of the Jaw

Multifocal brown tumor of the maxilla and mandible in primary hyperparathyroidism – diagnostic challenges and literature review

Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity

Contact Info

Product

Resources

About